Praxis Precision (PRAX) Medicines announced topline results from the Phase 2 RADIANT study evaluating vormatrigine in patients with focal onset seizures. Summary: Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency; Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days on treatment; Rapid and sustained response, with over 54% of patients achieving 50% response in the first week; Vormatrigine was generally well tolerated and continues to demonstrate favorable safety profile
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- PRAX Upcoming Earnings Report: What to Expect?
- Praxis Precision Medicines Gains FDA Breakthrough Designation
- Praxis Precision receives FDA Breakthrough Therapy Designation for relutrigine
- 3 Best Stocks to Buy Now, 7/15/2025, According to Top Analysts
- 3 Best Stocks to Buy Now, 7/11/2025, According to Top Analysts